Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT00733655
First received: August 12, 2008
Last updated: May 28, 2015
Last verified: August 2008
  Purpose

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to obtain small skin samples from patients with HHT in order to analyze the samples using histological methods, and study the properties of vascular endothelial cells derived from patients. We hypothesize that these cells will show altered growth, migration, and protein synthetic differences when compared to normal endothelial cells, which may be confirmed in single time point analyses in histological samples. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.


Condition
Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Biospecimen Retention:   Samples Without DNA

Histological samples


Estimated Enrollment: 50
Study Start Date: September 2008
Estimated Study Completion Date: August 2020
Estimated Primary Completion Date: August 2020 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with hereditary hemorrhagic telangiectasia (HHT)

Criteria

Inclusion Criteria:

  • Patients with Hereditary Haemorrhagic Telangiectasia

Exclusion Criteria:

  • Unable to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00733655

Locations
United Kingdom
Imperial College Hammersmith Campus
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Claire L Shovlin Imperial College London
  More Information

No publications provided

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT00733655     History of Changes
Other Study ID Numbers: IC/CLS5
Study First Received: August 12, 2008
Last Updated: May 28, 2015
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Telangiectasia, Hereditary Hemorrhagic
Telangiectasis
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Vascular Diseases
Vascular Malformations

ClinicalTrials.gov processed this record on July 26, 2015